Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (231-240 of 791) with videos related to

Pageof 80
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 15, 2012
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalitiesYiming Chen, Hagop Kantarjian, Zeev Estrov, et al.
Cancer|June 24, 2010
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimenDeborah Thomas, Susan O'Brien, Stefan Faderl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic responseHagop M Kantarjian, Jianqin Shan, Daniel Jones, et al.
Leukemia & Lymphoma|June 20, 2007
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring SystemMiloslav Beran, Sijin Wen, Yu Shen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemiaAhmed Awais, Constantine S Tam, Dimitrios Kontoyiannis, et al.
Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.
Cancer|March 29, 2002
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemiaJorge Cortes, Deborah Thomas, Adan Rios, et al.
Blood|November 19, 2005
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trialDeepa Sampath, Jorge Cortes, Zeev Estrov, et al.
Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 80

Showing results (231-240 of 791) with videos related to

Sort By:
Pageof 80
Clinical Lymphoma, Myeloma & Leukemia|May 15, 2012
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalitiesYiming Chen, Hagop Kantarjian, Zeev Estrov, et al.
Cancer|June 24, 2010
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimenDeborah Thomas, Susan O'Brien, Stefan Faderl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic responseHagop M Kantarjian, Jianqin Shan, Daniel Jones, et al.
Leukemia & Lymphoma|June 20, 2007
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring SystemMiloslav Beran, Sijin Wen, Yu Shen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemiaAhmed Awais, Constantine S Tam, Dimitrios Kontoyiannis, et al.
Cancer|March 29, 2002
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemiaMoshe Talpaz, Ashok Rakhit, Karen Rittweger, et al.
Cancer|March 29, 2002
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemiaJorge Cortes, Deborah Thomas, Adan Rios, et al.
Blood|November 19, 2005
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trialDeepa Sampath, Jorge Cortes, Zeev Estrov, et al.
Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 80